Valuation: Avenue Therapeutics, Inc.

Market Cap 1.09M 952K 877K 813K 1.54M 103M 1.57M 10.52M 4.09M 50.93M 4.08M 3.99M 176M P/E 2024
-0.22x
P/E 2025 -0.73x
Enterprise Value -1.77M -1.55M -1.43M -1.32M -2.51M -168M -2.55M -17.09M -6.65M -82.8M -6.64M -6.49M -286M EV / Sales 2024
-
EV / Sales 2025 -491,128x
Free-Float
86.49%
Yield 2024 *
-
Yield 2025 -
1 day+8.20%
1 week+17.86%
Current month+17.86%
1 month-6.38%
3 months-5.71%
6 months-56.00%
Current year-51.48%
1 week 0.25
Extreme 0.2501
0.33
1 month 0.25
Extreme 0.2501
0.36
Current year 0.15
Extreme 0.15
0.79
1 year 0.15
Extreme 0.15
0.97
3 years 0.15
Extreme 0.15
93.75
5 years 0.15
Extreme 0.15
2,767.51
10 years 0.15
Extreme 0.15
13,882.3
Manager TitleAgeSince
Chief Executive Officer 59 2022-07-31
Chief Executive Officer 36 2022-03-30
Investor Relations Contact - -
Director TitleAgeSince
Chairman 71 2015-02-08
Director/Board Member 69 2015-07-31
Chairman 68 2023-03-06
Date Insider Type Main position Quantity % Market Cap.
01-01FreeCompany 111,209 3.4934%
25-03-30FreeCompany 33,724 1.6419%
24-12-30OtherCompany 294,800 15.4214%
Change 5-day change 1-year change 3-year change Capi.($)
+8.20%+17.86%+3.51%-99.61% 1.09M
-0.81%+1.51%+73.58%+129.12% 57.72B
-3.80%-6.24%+67.04%+86.36% 52.65B
+1.17%+5.83%+16.39%+468.18% 24.46B
+0.38%+1.33%-14.32%-11.76% 23.84B
-3.05%+3.06%+42.36%-5.66% 19.28B
-0.33%+5.21%+44.38%-26.55% 17.8B
+3.46%+17.72%+206.66%+364.07% 17.29B
-6.73%+9.90%+36.04% - 15.28B
+2.79%+4.91%+29.26%+195.60% 14.35B
Average +0.13%+4.64%+50.49%+122.19% 24.27B
Weighted average by Cap. -1.14%+2.58%+57.63%+139.35%

Financials

2024 2025
Net sales - 1.4 1.23 1.13 1.05 1.99 133.25 2.02 13.58 5.28 65.76 5.27 5.16 227.3
Net income -11.65M -10.2M -9.4M -8.71M -16.53M -1.11B -16.8M -113M -43.82M -546M -43.75M -42.8M -1.89B -2.91M -2.55M -2.35M -2.17M -4.13M -276M -4.19M -28.13M -10.94M -136M -10.92M -10.68M -471M
Net Debt -2.59M -2.27M -2.09M -1.94M -3.68M -246M -3.74M -25.09M -9.76M -122M -9.74M -9.53M -420M -2.86M -2.5M -2.3M -2.13M -4.05M -271M -4.12M -27.61M -10.74M -134M -10.72M -10.49M -462M
Logo Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidate, intravenous tramadol (IV tramadol) is a novel therapy in development in the United States for managing post-operative pain as an alternative to conventional narcotics. The drug is designed to use a dual mechanism of action to block a patient’s pain signal with reduced abuse potential. This unique mechanism of action includes an opioid agonist and an inhibitor of norepinephrine and serotonin re-uptake.
Employees
1
Date Price Change Volume
26-07-06 US$0.3300 +8.20% 3,181

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATXI Stock